This study aims to study prospectively the clinical and paraclinical evolution and prognostic factors of autoimmune haemolytic anemias, Evans syndromes and chronic immunological thrombocytopenic purpura of children in France.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Complete sustainable remission (yes/no) for children with autoimmune haemolytic anemias
Timeframe: At the screening
complete remission (yes/no) for children with autoimmune haemolytic anemias
Timeframe: At the screening
partial remission (yes/no) for children with autoimmune haemolytic anemias
Timeframe: At the screening
no response (yes/no) for children with autoimmune haemolytic anemias
Timeframe: At the screening
deceased patient (yes/no) for children with autoimmune haemolytic anemias
Timeframe: At the screening
Complete sustainable remission (yes/no) for children with chronic immunologic thrombocytopenic purpura
Timeframe: At the screening
complete remission (yes/no) for children with chronic immunologic thrombocytopenic purpura
Timeframe: At the screening
partial remission (yes/no) for children with chronic immunologic thrombocytopenic purpura
Timeframe: At the screening
no response (yes/no) for children with chronic immunologic thrombocytopenic purpura
Timeframe: At the screening
deceased patient (yes/no) for children with chronic immunologic thrombocytopenic purpura
Timeframe: At the screening